Alyssa Abernathy
Family · Burlington, NCNPI 1104574920
Payments from drug & device makers
Across 224 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$578
- Pfizer$364
- Lilly USA, LLC$349
- AstraZeneca$299
- AbbVie$257
- Mylan Specialty L.p.$244
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,609100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $578 |
| Pfizer | 24 | $364 |
| Lilly USA, LLC | 23 | $349 |
| AstraZeneca | 17 | $299 |
| AbbVie | 14 | $257 |
| Mylan Specialty L.p. | 9 | $244 |
| Neurocrine Biosciences, Inc. | 6 | $142 |
| Axsome Therapeutics, Inc. | 7 | $130 |
| GSK | 6 | $111 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $103 |
| Corcept Therapeutics | 4 | $94 |
| Viatris Specialty LLC | 5 | $89 |
| Verona Pharma, Inc. | 3 | $84 |
| Insmed, Inc. | 4 | $77 |
| Exact Sciences | 4 | $67 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $61 |
| Actelion Pharmaceuticals US, Inc. | 3 | $58 |
| Merck | 3 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Dexcom, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Amgen | 2 | $28 |
| Electromed, Inc. | 2 | $26 |
| Philips North America LLC | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $23 |
| Organogenesis Inc. | 1 | $22 |
| Mannkind Corporation | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Bayer | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Medtronic | 1 | $16 |
| Exeltis, USA Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Abbott | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
$3,609 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 71 | $124,653 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $113,933 |
| OzempicSemaglutide | 83 | $110,149 |
| FarxigaDapagliflozin Propanediol | 78 | $74,058 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $52,094 |
| RybelsusSemaglutide | 32 | $45,046 |
| JardianceEmpagliflozin | 52 | $40,499 |
| LinzessLinaclotide | 32 | $34,408 |
| VraylarCariprazine Hcl | 21 | $33,815 |
| EliquisApixaban | 36 | $28,017 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 43 | $21,430 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $20,674 |
| XareltoRivaroxaban | 18 | $14,398 |
| QuliptaAtogepant | 13 | $14,213 |
| Spiriva HandihalerTiotropium Bromide | 18 | $13,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $578 | $155,195115 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $299 | $131,491175 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $111 | $126,234162 claims |
| Lilly USA, LLCMounjaro | $349 | $124,65371 claims |
| AbbVieLinzess, Vraylar, Qulipta | $257 | $82,43566 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $16 | $69,944110 claims |
| PfizerEliquis | $364 | $28,01736 claims |
| Astellas Pharma US IncVeozah, Myrbetriq | $19 | $10,88822 claims |
| MerckDulera | $51 | $4,71414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in Burlington
- Cheryl LindleyBurlington$19K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.